Administration of G-CSF for PBSC collection may unmask pre-existing IgA-nephropathy: A case report
- 14 September 2022
- journal article
- Published by Heighten Science Publications Corporation in Journal of Clinical Nephrology
- Vol. 6 (3), 079-082
- https://doi.org/10.29328/journal.jcn.1001094
Abstract
It is utterly important to ensure the safety of stem cell donors and limit the incidence of long-term adverse events. Additionally, the willingness to donate the potentially life-saving stem cells, depends among other reasons, on the donor’s trust in the safety of the procedure as our case highlights. Here we present the case of a 35-year-old patient who developed macrohematuria and proteinuria following peripheral blood stem cell (PBSC) donation. 4 years later he was diagnosed with IgA-nephropathy (IgAN) and the disorder was causally attributed to the PBSC donation. He discouraged his family and friends from registering as donors because of this. In the current case report, we review the literature on the relationship between IgAN and PBSC donation and suggest under which conditions stem cell donation can still be performed even with a prior diagnosis of IgAN.Keywords
This publication has 21 references indexed in Scilit:
- Relapsing Acute Kidney Injury Associated with PegfilgrastimCase Reports in Nephrology and Urology, 2012
- Possible involvement of G-CSF in IgA nephropathy developing in an allogeneic peripheral blood SCT donorBone Marrow Transplantation, 2010
- The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classificationKidney International, 2009
- Severe events in donors after allogeneic hematopoietic stem cell donationHaematologica, 2009
- Recovery and Safety Profiles of Marrow and PBSC Donors: Experience of the National Marrow Donor ProgramTransplantation and Cellular Therapy, 2008
- Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challengesBlood, 2008
- Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports projectBone Marrow Transplantation, 2007
- Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) projectBritish Journal of Haematology, 2006
- Severe chronic neutropenia: Treatment and follow‐up of patients in the Severe Chronic Neutropenia International RegistryAmerican Journal of Hematology, 2003
- Long‐term safety of treatment with recombinant human granulocyte colony‐stimulating factor (r‐metHuG‐CSF) in patients with severe congenital neutropeniasBritish Journal of Haematology, 1994